Abstract
Acquired resistance of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) has been developed as an important clinical problem though EGFR-TKI such as gefitinib, erlotinib and afatinib [1,2] has achieved 8-14 months of progression free survival in advanced non-small cell lung cancer (NSCLC) patient with EGFR mutation. We report a case here that an advanced lung adenocarcinoma with L858R mutation responded well to pemetrexed rechallenge after acquired resistance of erlotinib.
Keywords:
Acquired resistance; Chemotherapy; EGFR-TKI; NSCLC; Pemetrexed; Rechallenge.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.
MeSH terms
-
Adenocarcinoma / diagnostic imaging*
-
Adenocarcinoma / drug therapy
-
Adenocarcinoma / genetics
-
Adenocarcinoma / secondary
-
Antineoplastic Combined Chemotherapy Protocols / pharmacology
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
DNA Mutational Analysis
-
Drug Resistance, Neoplasm / genetics*
-
ErbB Receptors / antagonists & inhibitors
-
ErbB Receptors / genetics
-
Erlotinib Hydrochloride
-
Glutamates / administration & dosage
-
Guanine / administration & dosage
-
Guanine / analogs & derivatives
-
Humans
-
Lung Neoplasms / diagnostic imaging*
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / genetics
-
Lung Neoplasms / pathology
-
Maintenance Chemotherapy
-
Male
-
Middle Aged
-
Mutation, Missense
-
Neoplasm Recurrence, Local / diagnostic imaging*
-
Neoplasm Recurrence, Local / prevention & control
-
Pemetrexed
-
Quinazolines / administration & dosage
-
Radiography
-
Treatment Outcome
Substances
-
Glutamates
-
Quinazolines
-
Pemetrexed
-
Guanine
-
Erlotinib Hydrochloride
-
EGFR protein, human
-
ErbB Receptors